Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Endocrinol Invest ; 31(12): 1079-85, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19246974

RESUMO

INTRODUCTION: Corticotropin-releasing factor (CRF) plays a central role in controlling the hypothalamic-pituitary-adrenal (HPA) axis during stressful periods. CRF is synthesized and secreted in the hypothalamic paraventricular nucleus (PVN) in response to stress, and stimulates ACTH in the pituitary corticotrophs. ACTH stimulates the release of glucocorticoids from the adrenal glands, and glucocorticoids sequentially inhibit hypothalamic PVN production of CRF and pituitary production of ACTH. The effects of glucocorticoids on CRF gene regulation, however, are possibly tissue-specific since glucocorticoids stimulate CRF gene expression in the placenta and the bed nucleus of the stria terminalis, while they inhibit it in the hypothalamus. METHODS AND RESULTS: In a hypothalamic cell line, 4B, we found that forskolin-stimulated CRF gene transcription was mediated by a functional cAMP-response element (CRE), which included -220 to -233 bp on the CRF 5'-promoter region. Protein kinase A, protein kinase C, and p38 mitogen-activated protein kinase pathways contributed to forskolin-induced transcriptional activity of CRF in hypothalamic 4B cells. Glucocorticoid-dependent repression of cAMP-stimulated transcriptional activity of CRF was localized to promoter sequences between -278 and -233 bp, which included a glucocorticoid regulatory element and a serum response element. CONCLUSION: Taken together, these findings indicate that the regulatory elements, including CRE, negative glucocorticoid regulatory element, and a serum response element on the promoter, contribute to the regulation of CRF gene transcription in hypothalamic 4B cells.


Assuntos
Hormônio Liberador da Corticotropina/genética , Hipotálamo/metabolismo , Elementos Reguladores de Transcrição/fisiologia , Antracenos/farmacologia , Linhagem Celular , Cromonas/farmacologia , Colforsina/farmacologia , Hormônio Liberador da Corticotropina/metabolismo , Dexametasona/farmacologia , Flavonoides/farmacologia , Genes Reporter/efeitos dos fármacos , Humanos , Hipotálamo/efeitos dos fármacos , Imidazóis/farmacologia , Isoquinolinas/farmacologia , Morfolinas/farmacologia , Regiões Promotoras Genéticas/efeitos dos fármacos , Regiões Promotoras Genéticas/fisiologia , Inibidores de Proteínas Quinases/farmacologia , Piridinas/farmacologia , Elementos Reguladores de Transcrição/efeitos dos fármacos , Deleção de Sequência , Sulfonamidas/farmacologia , Transfecção
2.
J Endocrinol Invest ; 30(11): 957-61, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18250618

RESUMO

We describe a rare, but interesting, case of TSH-producing adenoma (TSHoma), accompanied by increases in both anti-TSH receptor antibody (TRAb) and thyroid-stimulating antibody (TSAb) after tumor resection. A 21-yr-old woman was referred to our department for further evaluation of pituitary tumor. In a nearby hospital, she had been diagnosed as having pituitary tumor. Her serum free T4, free T3, and TSH levels were all elevated concomitantly. On the basis of a diagnosis of pituitary adenoma with TSH production, transsphenoidal resection of the pituitary adenoma was performed. Two weeks after the operation, the blood concentrations of TSH were undetectable, whereas both TRAb and TSAb levels were elevated. TSAb levels gradually increased further from 2 weeks to 3 months after the operation, accompanied by an increase in TSH and free T4 levels. TSH is an important hormone in maintaining physiology and regulating immunomodulators in thyrocytes, as it can influence a variety of immune-regulating cytokine-like activities and inhibit expressions of Fas antigen, intracellular adhesion molecule-1, and class II trans-activator. Changes in TSH would modulate the immune circumstances in the thyroid, and then induce TRAb and TSAb. Autoimmune parameters with thyroid function should be observed carefully when managing patients with TSHoma.


Assuntos
Adenoma/metabolismo , Anticorpos Anti-Idiotípicos/sangue , Neoplasias Hipofisárias/metabolismo , Receptores da Tireotropina/imunologia , Tireotropina/metabolismo , Adenoma/imunologia , Adenoma/cirurgia , Adulto , Feminino , Humanos , Imunoglobulinas Estimuladoras da Glândula Tireoide/sangue , Neoplasias Hipofisárias/imunologia , Neoplasias Hipofisárias/cirurgia , Hormônios Tireóideos/sangue
3.
J Endocrinol Invest ; 29(10): 928-33, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17185904

RESUMO

Hypokalemic periodic paralysis (HypoPP) is a skeletal muscle disorder in which episodic attacks of muscle weakness occur; they are associated with decreased serum potassium (K+) levels. Recent molecular approaches have clarified that the condition is caused by mutations in the skeletal muscle voltage-gated calcium channel 1 subunit (CACNA1S). We describe two unrelated patients with HypoPP, followed by their relevant clinical studies and gene analysis. Clinical studies included an oral glucose tolerance test (OGTT), food-loading and insulin tolerance tests (ITT). For Case 1, serum K+ levels were extremely decreased following insulin tolerance testing compared with levels for controls. These results support the hypothesis that no efflux of K+ ion occurs in patients because of low activity of adenosine triphosphate (ATP)-sensitive K+ channel (KATP) channels. Mutational analysis of the CACNA1S gene showed a duplicate insertion of 14 base pairs (bp) from 52 to 65 in intron 26, present in the heterozygous state in both patients. No other mutations were detected in the CACNA1S gene, the muscle sodium channel gene (SCN4A) or the voltage-gated K+ channel gene (KCN3) of either patient. Further analysis showed that this duplicate insertion of 14 bp in intron 26 of the CACNA1S gene was found in 23.7% of healthy subjects. K+ dynamics studies are useful for confirming this syndrome, while further gene analysis for various ion channels using amplification and direct sequencing are required to evaluate the molecular basis of the disorder in the individual patient.


Assuntos
Canais de Cálcio/genética , Paralisia Periódica Hipopotassêmica/genética , Paralisia Periódica Hipopotassêmica/fisiopatologia , Mutação/genética , Adulto , Canais de Cálcio/fisiologia , Canais de Cálcio Tipo L , DNA/genética , Humanos , Paralisia Periódica Hipopotassêmica/diagnóstico , Canal de Potássio Kv1.3/genética , Canal de Potássio Kv1.3/fisiologia , Masculino , Canal de Sódio Disparado por Voltagem NAV1.4 , Potássio/sangue , Análise de Sequência de DNA , Canais de Sódio/genética , Canais de Sódio/fisiologia
4.
J Endocrinol Invest ; 28(9): 822-6, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16370563

RESUMO

Gitelman's syndrome is a recessively inherited renal tubular disorder characterized by low plasma potassium and magnesium levels, reduced calcium excretion, metabolic alkalosis, and increased plasma renin activity and plasma aldosterone concentration with normal blood pressure levels. A 23-yr-old man was referred to our department for further evaluation of hypokalemia. The patient also had hypomagnesemia and markedly reduced urinary calcium excretion. Renal clearance studies and gene analysis of the thiazide-sensitive Na-Cl cotransporter (TSC) were performed in the patient. In response to an iv injection of furosemide, chloride clearance (CCl) increased markedly, while distal fractional chloride reabsorption CH2O/(CH2O+CCl) was considerably reduced. In contrast, thiazide ingestion had no significant effects on these parameters. The patient had compound heterozygous mutations in the alleles encoding the TSC gene, one of which has not been formerly reported. Renal clearance studies and TSC gene analysis by amplification and direct sequencing are useful diagnostic tools for confirming a diagnosis of Gitelman's syndrome.


Assuntos
Nefropatias/diagnóstico , Nefropatias/genética , Mutação , Receptores de Droga/genética , Simportadores de Cloreto de Sódio/genética , Adulto , Sequência de Aminoácidos , Cálcio/urina , Cloretos/farmacocinética , Furosemida , Heterozigoto , Humanos , Hipopotassemia/diagnóstico , Hipopotassemia/genética , Testes de Função Renal/métodos , Magnésio/sangue , Masculino , Dados de Sequência Molecular , Síndrome , Tiazidas
6.
Neuroimmunomodulation ; 3(4): 254-8, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-9094448

RESUMO

We examined the influence of gender and gonadectomy on the plasma adrenocorticotropin (ACTH) response to intravenous administration of human recombinant interleukin (IL)-1beta (3 microg/kg) in the rat. For comparison, we also examined whether gender and gonadectomy affect ACTH secretion after immobilization stress (a 30-min period), which is a nonimmunological stressor. IL-1beta induced a significantly higher ACTH response in females than in males, and this sexual difference was abolished by gonadectomy in both sexes. By contrast, ACTH secretion after immobilization was statistically the same in males and females, but tended to be higher in gonadectomized males than in gonadectomized females. These results may suggest a dissociative regulation by gonadal steroids of IL-1beta- and immobilization-induced ACTH responses in the rat. The sexual difference in ACTH response to IL-1beta may represent another example of the sexually dimorphic immunological activity, which is known to be higher in females than in males.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Castração , Interleucina-1/farmacologia , Caracteres Sexuais , Estresse Fisiológico/metabolismo , Animais , Feminino , Imobilização , Masculino , Ratos , Ratos Wistar
7.
Eur J Endocrinol ; 133(3): 317-9, 1995 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-7581948

RESUMO

We experienced an extremely unusual combination of Cushing's disease and corticosteroid-binding globulin (CBG) deficiency that has been reported in only one similar case to date. A 53-year-old woman presented at a medical clinic with clinical Cushing's disease. However, her plasma levels of adrenocorticotropin (ACTH) and cortisol were in the normal range. Six months later, during a second visit, a high urinary excretion of 17-hydroxycorticosteroids was found, but plasma ACTH and cortisol levels were normal again. Further investigation revealed a decreased CBG concentration. Free plasma cortisol levels were clearly elevated. Furthermore, the Cushing's disease of our patient was complicated by periodic secretion of ACTH and cortisol, with high or normal outputs of corticosteroids occurring alternately every 1-3 days, which explained the occasionally normal plasma ACTH and cortisol levels. A combination of a decreased serum CBG concentration and periodic secretion of ACTH can be an important pitfall in the diagnosis of Cushing's disease.


Assuntos
Síndrome de Cushing/diagnóstico , Transcortina/deficiência , 17-Hidroxicorticosteroides/urina , Hormônio Adrenocorticotrópico/sangue , Hormônio Adrenocorticotrópico/metabolismo , Síndrome de Cushing/complicações , Feminino , Humanos , Hidrocortisona/sangue , Hidrocortisona/metabolismo , Pessoa de Meia-Idade , Periodicidade
8.
Biochem Biophys Res Commun ; 200(2): 1111-7, 1994 Apr 29.
Artigo em Inglês | MEDLINE | ID: mdl-8179590

RESUMO

It has been demonstrated in several animal species that neuropeptide Y (NPY) exerts a modulatory effect on luteinizing hormone (LH) secretion. However, whether NPY plays a similar role also in humans has yet to be determined. Therefore, in this study we examined the effect of human NPY on the anterior pituitary hormone secretion in 6 normal men. Intravenous bolus injection of 100 micrograms of human NPY alone did not affect the secretion of any anterior pituitary hormone or cortisol. However, when NPY (100 micrograms) was administered simultaneously with LH-releasing hormone (LHRH, 100 micrograms), a significant potentiation was observed for LHRH-induced LH secretion. Similarly, follicle-stimulating hormone (FSH) response to LHRH was slightly potentiated by the coadministration of NPY, although this effect was not statistically significant. This is the first study to demonstrate that NPY can augment the LHRH-induced LH secretion in humans.


Assuntos
Hormônio Liberador de Gonadotropina/administração & dosagem , Hormônio Luteinizante/metabolismo , Neuropeptídeo Y/administração & dosagem , Adulto , Sinergismo Farmacológico , Hormônio Foliculoestimulante/metabolismo , Humanos , Injeções Intravenosas , Masculino , Adeno-Hipófise/efeitos dos fármacos , Adeno-Hipófise/metabolismo , Hormônios Adeno-Hipofisários/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA